What it is
Cardiogen is a synthetic peptide of four amino acids: alanine, glutamic acid, aspartic acid and arginine. The St Petersburg laboratory led by V. Khavinson, which names each of its short synthetic peptides after an organ, assigns this one to the heart. Its relatives in this library include epitalon, the programme's best-known tetrapeptide, and vesugen, its blood-vessel tripeptide.
How sure is the sequence? The study abstracts that name cardiogen call it "the synthetic tetrapeptide cardiogen" without printing the letters. The pairing of the name with AEDR comes from the programme's own 2021 review (PMID 34834147), whose full text holds both terms. A 2013 paper lists Ala-Glu-Asp-Arg among six short peptides tested on wheat histones, without the trade name (PMID 23581987). Epitalon is Ala-Glu-Asp-Gly, so the two differ only in the last amino acid.
PubChem has no record for the peptide under either name. The formula C18H31N7O9 and the weight of about 489.5 in this entry are our arithmetic from the four residues, not a database value.
Change the last residue and the series moves to another organ: Ala-Glu-Asp-Leu is Bronchogen, the lung-labelled tetrapeptide, and Ala-Glu-Asp-Pro is Cortagen.
Three other things called cardiogen
A search for this name returns more noise than signal, and the confusion matters.
| Name | What it is | Where it turned up |
|---|---|---|
| CardioGen-82 | A strontium-82/rubidium-82 generator for PET scans of the heart, FDA-approved, recalled in 2011 over strontium exposure | 6 of the 19 PubMed records; 1 ClinicalTrials.gov study (NCT01424774) |
| CARDIOGEN | A French clinical network for inherited heart disease; also a Hungarian registry | PubMed records from 2017 and 2025 |
| "cardiogen" as a synonym | PubChem resolves the word to a carnitine record (CID 10917, C7H15NO3) | PubChem name search, 2026-11-13 |
None of these is the peptide.
What the research shows
A PubMed search on 2026-11-13 returned 19 records with "cardiogen" in the title or abstract. By this entry's reading of the abstracts, four concern the peptide.
| Year | Model | What the abstract reports | PMID |
|---|---|---|---|
| 2006 | Tissue cultures from young and old rats | Cardiogen and three related peptides stimulated their matching tissues at 0.05 ng/ml | 17152728 |
| 2009 | Heart-muscle explants from 3- and 24-month-old rats | Stimulated cell proliferation in both ages; lower p53 expression, which the authors read as less cell death | 20210190 |
| 2009 | Old rats with transplanted M-1 sarcoma | Dose-dependent slowing of tumour growth, with bleeding tissue death and more tumour-cell death; the authors point to the tumour's blood vessels | 20396706 |
| 2010 | Ageing cultures of human prostate fibroblasts | Three peptides raised signalling markers; a different peptide, T-38, was "the most active" | 20586252 |
Two points the table does not show. The first three studies are rat work; the fourth used human cells in a dish, not people. And the 2009 pair pulls in opposite directions on the page: one reports more cell growth in heart tissue, the other more cell death in a tumour. The authors do not treat these as contradictory, but no independent group has tested either.
What is not established
- A heart effect in a living person. Every result above comes from rat tissue, rats or a dish of prostate cells; the heart-muscle finding is cell proliferation in explants, which is not the same thing as a working heart pumping better.
- Which way the growth signal cuts. More proliferation in heart explants and more cell death in a sarcoma were reported from the same programme in the same year. Whether one peptide can do both in one body was never tested.
- Any human safety record. Nobody has reported giving cardiogen to people, so there is no figure for side effects at any amount.
- That AEDR arrives where it is aimed. None of the four abstracts follows the tetrapeptide after it is given, so whether it reaches heart muscle intact is unknown. The series' other tetrapeptide sold for an organ, Prostamax, has a record made up entirely of chromatin studies.
- Confirmation by another laboratory. No study from outside the originating programme is indexed, and nothing at all has appeared on the peptide since 2010.
Where it stands
- Regulatory status: no approval of the AEDR peptide found; the approved product with the same-sounding name is the CardioGen-82 scan generator, which is not a peptide.
- Where readers meet it: research-chemical listings and multi-peptide bioregulator blends sold for the heart. Products are outside this library's scope.
- Size of the record (2026-11-13): four peptide papers, 2006–2010, none since; of four ClinicalTrials.gov name matches, none studies the peptide.
Related reading
The shortest member of the family is Vilon, a dipeptide, and the reproductive-labelled one is testagen. Peptides the heart itself makes are described in the natriuretic peptides entry. For how longevity claims for this family compare with their human evidence, see the longevity overview.
